Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Arcadia Biosciences (Nasdaq: RKDA) said it closed a $4 million private placement under Nasdaq rules, selling 3,883,496 shares of common stock (or pre-funded warrants) plus Series A-1 and A-2 preferred investment options to buy up to 3,883,496 shares each at $1.03/share. Gross proceeds were about $4 million. H.C. Wainwright & Co. was placement agent; proceeds will fund working capital and general corporate purposes.

Original reporting
Published Jun 13, 2026, 2:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 13, 2026, 2:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules — source image
Decision brief

The 30-second read

$RKDANeutralMed
01

Why it matters

Traders should model dilution from the 3,883,496 share equivalent issuance and consider future overhang from Series A-1/A-2 option exercises (exercise price $0.91) and the timing constraints tied to stockholder approval and resale registration.

02

Market read

Closed financing at $1.03/share with $0.91 exercise options; the key tradable variable is dilution/overhang versus reduced funding-risk.

03

What to watch

Series A-1 requires stockholder approval to become exercisable; timing of approval and the resale registration process can delay/shape when dilution actually hits the tape.

Relevance 9/10Novelty 8/10Timing: today/this week after-hours-to-next-session positioning around the closed financing

Background

Arcadia announced and then closed an at-the-market priced private placement under Nasdaq rules, using common stock and preferred investment options (with pre-funded warrants in lieu).

Company-level read

Ticker impact

$RKDANeutralMedium confidence
Context

Arcadia Biosciences closed a $4M at-the-market private placement for 3,883,496 shares (or pre-funded warrants) at $1.03/share, plus Series A-1/A-2 options.

Expected impact

Likely near-term pressure/volatility from dilution overhang, partially offset by cash proceeds; direction depends on whether the market views the financing as sufficient runway.

Evidence & confidence

The article discloses the closing, pricing, share count, and option exercise terms, which directly inform dilution and future selling/exercise risk.

Market effects

Adds another small-cap biotech/wellness financing datapoint; may reinforce risk premium for pre-revenue/early-stage issuers using ATM + preferred option structures.

No specific regional spillover beyond US microcap sentiment.

Limited; primarily affects RKDA’s capital structure and investor base.

Counterpoint

If the company’s cash runway was the key overhang, the $4M gross proceeds could reduce near-term funding risk more than the market discounts dilution.

Key entities

  • Arcadia Biosciences, Inc.

    Nasdaq-listed company (RKDA) that closed the $4M private placement and disclosed pricing and option exercise terms.

  • H.C. Wainwright & Co.

    Exclusive placement agent for the offering.

Related articles

$RKDAMed

Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights -- Zola ® Q3 revenues increase 24% year-over-year, largest quarterly sales ever -- -- New 1L espresso formulation ships this month, slim cans to launch in early 2027 --

$RKDAMed

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights – Net cash used in operating activities only $319K in the second quarter – – Arcadia closes $4 million private placement; ends second quarter with $4.2 m

$NVDAHigh

Using honeytraps for advantage is a strategy that goes back centuries

Nvidia CEO Jensen Huang resigned after reports of extramarital affairs, one with Alice Huang, a Singapore-based executive linked to Chinese intelligence. Nvidia denies any company secrets were leaked, but the incident has raised national security concerns due to the company's role in AI and semiconductors. China denies espionage allegations. The case has drawn comparisons to historical 'honeytrap' tactics used in political and military strategies.

$TSLAMed

Key facts: Tesla-SpaceX Committees Explore Combination; Italy Approves Driving System

Tesla and SpaceX formed committees to explore a potential merger, with discussions possible at Tesla's December shareholder meeting. Tesla shares fell 3% on the news. HSBC upgraded TSLA to Hold, setting a $359 target. Tesla received Italian approval for its Level 2 Assisted Driving system, launching at €99/month. The company also expanded Cybercab operations in Dallas and plans a €3 billion German plant. Analysts raised concerns about funding and regulatory risks for a merger.